Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CNCE

Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

Concert Pharmaceuticals logo

About Concert Pharmaceuticals Stock (NASDAQ:CNCE)

Advanced Chart

Key Stats

Today's Range
$8.37
$8.37
50-Day Range
$8.33
$8.40
52-Week Range
$2.66
$8.55
Volume
N/A
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Headlines

CNCE Stock Analysis - Frequently Asked Questions

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.25 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Concert Pharmaceuticals investors own include Intel (INTC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Global Blood Therapeutics (GBT), Micron Technology (MU), Pfizer (PFE) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/09/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-80,050,000.00
Pretax Margin
-300,735.69%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Price / Cash Flow
N/A
Book Value
$3.24 per share
Price / Book
2.58

Miscellaneous

Free Float
42,507,000
Market Cap
$401.26 million
Optionable
Optionable
Beta
0.52

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:CNCE) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners